Immunotherapies and Systems Medicine of Melanoma and Autoimmunity: Recent Advances and Challenges
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 393
Special Issue Editor
2. Department Life, Light and Matter, University of Rostock, 18059 Rostock, Germany
Interests: cancer metastasis; immune microenvironment; tumor progression and heterogeneity; drug resistance; adenoviral cell reprogramming technology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Melanoma is the most serious skin cancer capable of becoming metastatic, drug-refractory, and lethal if managed late or inappropriately. The mechanisms underlying its aggressiveness and therapy resistance are variegated. Tumor-intrinsic factors related to the genetic, transcriptional, or functional profile of melanoma cells are among the most important regulators of the tumor microenvironment, controlling the immunological antitumor response. To combat this cancer, the last decade has seen a radical paradigm shift away from traditional treatment strategies towards a myriad of immunotherapy. Coupled with their success, a significant proportion of melanoma patients are concomitantly diagnosed with autoimmune diseases, either as a pre-existing condition or as a sequelae of immune-based therapy, complicating clinical management and raising the demand for novel biomarkers for patient-specific diagnosis and precision immunotherapy.
This Special Issue focuses on recent advances and challenges in melanoma immunotherapies and systems medicine of melanoma and autoimmunity. These include currently available strategies for the implementation of personalized immunotherapy, functional and clinical association analyses exploring how tumor heterogeneity (at the genome, transcriptome/proteome, and epigenome levels) affects the immune microenvironment, and cutting-edge delivery technologies for cancer immunotherapy. Of particular interest are studies providing mechanistic insights into the impact of immune therapeutics on adverse autoimmunologic events. In this Special Issue, we welcome a variety of submissions, including reviews and original research articles.
Prof. Dr. Brigitte Pützer
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma immune cell crosstalk
- cancer heterogeneity
- tumor immune microenvironment (TIME)
- cytokine-based immunotherapies
- cancer and nanovaccines
- CAR-T cell therapy
- immune checkpoint inhibitors
- immune-related adverse events (irAE)
- gut microbiome
- drug delivery systems
